LMAT vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LMAT exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and exceptional liquidity, but it is currently facing a severe valuation disconnect. While the company shows strong growth (41.4% earnings growth) and high gross margins, the current price of $114.62 significantly exceeds both the Graham Number ($31.3) and the growth-based Intrinsic Value ($74.34). This premium is further complicated by heavy insider selling, including a large divestment by the CEO, and a bearish technical trend despite the price being near 52-week highs.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LMAT vs MRK: Head-to-Head Comparison
This page compares LeMaitre Vascular, Inc. (LMAT) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.